Wegovy Maintains Market Dominance Despite Eli Lilly GLP-1 Launch

Wegovy continues to lead the GLP-1 market among weight-loss medications, despite competition from Eli Lilly's Foundayo. Specific market share percentages or sales figures were not provided. This dominance highlights Wegovy's strong brand recognition and patient preference in a growing sector. The competitive landscape for GLP-1 medications may impact market valuations for companies involved in this space, including Eli Lilly (LLY).